GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders

  • AstraZeneca signed on PsychoGenics to evaluate a number of its drug candidates for their potential to treat psychiatric disorders. The company will use its high-throughput drug discovery platforms that combine behavioral neurobiology with robotics, bioinformatics, and computer vision.

    PsychoGenics will receive research payments and milestones commensurate with the stage of development. The company is also entitled to royalties on any future sales.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?